Long-Term Melatonin Linked to 90% Higher Heart Failure Risk

A new American Heart Association study found chronic insomniacs who used melatonin for a year or more had a 90% higher risk of developing heart failure.

@sharedot

Long-Term Melatonin Linked to 90% Higher Heart Failure Risk

By @sharedot · · 6 pages

  • Health
  • Heart Health
  • Melatonin
  • Sleep

A new American Heart Association study found chronic insomniacs who used melatonin for a year or more had a 90% higher risk of developing heart failure.

What the study found

According to Futurism, a new piece of research published by the American Heart Association found that chronic insomniacs who took melatonin supplements for 12 months or more had a 90 percent higher risk of developing congestive heart failure over a five-year period than those who did not use the sleep aid.

The researchers split a large group of chronic insomniacs into two cohorts — long-term melatonin users and non-users — and tracked their cardiovascular outcomes.

Lead author Ekenedilichukwu Nnadi, chief resident in internal medicine at SUNY Brooklyn, said it was striking to see such consistent and significant increases in serious health outcomes, even after balancing for many other risk factors.

Why the result is surprising

Melatonin gummies and pills are widely treated as a harmless, 'natural' over-the-counter sleep aid used by tens of thousands of people, which is exactly why the findings landed hard.

Futurism reports that a secondary analysis found melatonin users were nearly 3.5 times more likely to be hospitalized for heart failure, with hospitalization rates of 19.0 percent versus 6.6 percent in the control group.

Overall, 4.6 percent of the melatonin group developed heart failure compared with 2.7 percent of the control group. 'Melatonin supplements may not be as harmless as commonly assumed,' Nnadi said, adding that if confirmed the results could change how doctors counsel patients about sleep aids.

Important caveats on the evidence

Before anyone flushes their gummies, the study has real limitations.

According to Futurism, the findings were not drawn from a randomized clinical trial but from a large database of anonymous health records covering chronic insomniacs, split into those who dosed the hormone for 12 months or more and those who did not.

The researchers themselves say more in-depth research is needed to confirm the results.

That caution is a familiar theme in cardiovascular science this week: BioPharma Dive reports that Novartis and Ionis' pelacarsen failed to cut heart attacks, strokes and death in a large Phase 3 trial even though it lowered Lp(a) levels, a reminder that promising risk-marker signals do not always translate into proven outcomes.

The stakes and what comes next

If the association is confirmed by stronger trial evidence, Futurism notes it could affect how doctors counsel patients about sleep aids and reshape assumptions about a supplement most people consider benign.

The field will be watching closely: the same week, BioPharma Dive reported that analysts are combing through pelacarsen's failed trial data for correlations between biomarker reduction and clinical benefit, underscoring how much cardiovascular drug and supplement research now hinges on whether early signals hold up under scrutiny.

Sources

  1. futurism.com › Melatonin Use Linked to Massively Increased Risk of Heart Failure
  2. biopharmadive.com › Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

More on Health